WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage ...

Sionna including strong clinical execution across multiple programs. Encouraging interim Phase 1 data for SION-719 and SION-451, our highly potent nucleotide-binding domain 1 stabilizers, showed that ...

In this article, we are going to take a look at where Sionna Therapeutics, Inc. (NASDAQ:SION) stands against other stocks with at least $10 million in insider spending recently. Since Donald Trump ...

We recently published a list of 10 Stocks With At Least $20 Million In Insider Spending Recently. In this article, we are going to take a look at where Sionna Therapeutics, Inc.

March 20, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In this article, we are going to take a look at where Sionna Therapeutics, Inc. (NASDAQ:SION) stands against other stocks with at least $10 million in insider spending recently. Since Donald Trump ...

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cystic fibrosis (CF). It develops nucleotide-binding domain 1 (NBD1) stabilizers that ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

In this article, we are going to take a look at where Sionna Therapeutics, Inc. (NASDAQ:SION) stands against other stocks with at least $20 million in insider spending recently. As the stock ...